The FDA approves the combination of Pfizer’s (NYSE:PFE) Braftovi (encorafenib) and Eli Lilly’s (NYSE:LLY)
Erbitux (cetuximab) for the treatment of adults with BRAF V600E
mutation-positive metastatic colorectal cancer who have received prior
therapy, a Priority Review and Breakthrough Therapy indication.
A pivotal late-stage showed that the combo extended overall survival compared to cetuximab + chemo.
https://seekingalpha.com/news/3559539-fda-oks-pfizers-braftovi-combo-for-certain-type-of-colorectal-cancer
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.